The protective association of endogenous immunoglobulins against sepsis mortality is restricted to patients with moderate organ failure

Annals of Intensive Care

Volumn 7, Issue 1, 2017, Pages

  Martin Loeches, Ignacio ^a   Muriel Bombín, Arturo ^b   Ferrer, Ricard ^c,d   Artigas, Antonio ^d,e,f   Sole Violan, Jordi ^d,g   Lorente, Leonardo ^d,h   Andaluz Ojeda, David ⁱ   Prina Mello, Adriele ^j   Herrán Monge, Ruben ^b   Suberviola, Borja ^d,k   Rodriguez Fernandez, Ana ^k   Merino, Pedro ^b   Loza, Ana M ^d,l   Garcia Olivares, Pablo ^d,m   Anton, Eduardo ^d,n   Tamayo, Eduardo ⁱ   Trapiello, Wysali ⁱ   Blanco, Jesús ^b,f   Bermejo Martin, Jesús F ⁱ   García García, Marta María ^o   Pueyo, Mª JesúsLópez ^o   Ratero, Jose Antonio Fernandez ^o   Barrios, Miguel Martinez ^o   Torre, FernandoCallejo ^o   Echeverri, Sergio Ossa ^o   Ule, Demetrio Carriedo ^o   Berrot, Ana Mª Domínguez ^o   Domínguez, Fco Javier Díaz ^o   Moradillo, Susana ^o   Martínez, Braulio Alvarez ^o   Albalá, Noelia ^o   Ballesteros, Juan Carlos ^o   Perez, Marta Paz ^o   Losada, Elena Perez ^o   Macías, Santiago ^o   García, RafaelPajares ^o   Cervigón, Noelia Recio García ^o   Serrano, Mª Mar Gobernado ^o   Calavia, Mª José Fernández ^o   Torres, Daniel Moreno ^o   Tarancón, Concha ^o   Loreto, Teresa ^o   Carcelen, Priscila ^o   Gandía, Rafael Cítores y Francisco ^o   more..

^a ST JAMES S HOSPITAL   (Ireland)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^h HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^j TRINITY COLLEGE DUBLIN   (Ireland)

^k HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^l HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^m HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁿ HOSPITAL DE MANACOR   (Spain)

^o Hospital de Manacor ^*

more..

Author keywords

Immunoglobulins; Sepsis; Severity; Survival

Indexed keywords

ALBUMIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M;

AGED; ARTICLE; CHRONIC LIVER FAILURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HOSPITAL MORTALITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL TIME;

EID: 85018503351     PISSN: None     EISSN: 21105820     Source Type: Journal    
DOI: 10.1186/s13613-017-0268-3     Document Type: Article

References (21)

1. Almansa R, Tamayo E, Andaluz-Ojeda D, Nogales L, Blanco J, Eiros JM, et al. The original sins of clinical trials with intravenous immunoglobulins in sepsis. Crit Care Lond Engl. 2015;19:90.
2. Shankar-Hari M, Culshaw N, Post B, Tamayo E, Andaluz-Ojeda D, Bermejo-Martín JF, et al. Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis. Intensive Care Med. 2015;41:1393–401.
3. Dietz S, Lautenschläger C, Müller-Werdan U, Pilz G, Fraunberger P, Päsler M, et al. Serum IgG levels and mortality in patients with severe sepsis and septic shock: the SBITS data. Med. Klin. Intensivmed. Notfallmedizin. 2016;1–9.
4. Bermejo-Martín JF, Rodriguez-Fernandez A, Herrán-Monge R, Andaluz-Ojeda D, Muriel-Bombín A, Merino P, et al. Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Intern Med. 2014;276:404–12.
5. Bermejo Martin JF, Giamarellos-Bourboulis EJ. Endogenous immunoglobulins and sepsis: New perspectives for guiding replacement therapies. Int J Antimicrob Agents. 2015;46(Suppl 1):S25–8.
6. Andaluz-Ojeda D, Nguyen HB, Meunier-Beillard N, Cicuéndez R, Quenot J-P, Calvo D, et al. Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity. Ann Intensive Care. 2017;7:15.
7. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.
8. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:775–87.
9. Herrán-Monge R, Muriel-Bombín A, García-García MM, Merino-García PA, Cítores-González R, Fernández-Ratero JA, et al. Mortality reduction and long-term compliance with surviving sepsis campaign: A Nationwide Multicenter Study. Shock Augusta Ga. 2016;45:598–606.
10. Sánchez B, Ferrer R, Suarez D, Romay E, Piacentini E, Gomà G, et al. Declining mortality due to severe sepsis and septic shock in Spanish intensive care units: a two-cohort study in 2005 and 2011. Med Intensiva. 2017;41:28–37.
11. Bermejo-Martin JF, Andaluz-Ojeda D, Almansa R, Gandía F, Gómez-Herreras JI, Gomez-Sanchez E, et al. Defining immunological dysfunction in sepsis: a requisite tool for precision medicine. J Infect. 2016;72:525–36.
12. Bermejo-Martin JF, Tamayo E, Andaluz-Ojeda D, Martín-Fernández M, Almansa R. Characterizing systemic immune dysfunction syndrome to fill in the gaps of SEPSIS-2 and SEPSIS-3 definitions. Chest. 2017;151:518–9.
13. Almansa R, Wain J, Tamayo E, Andaluz-Ojeda D, Martin-Loeches I, Ramirez P, et al. Immunological monitoring to prevent and treat sepsis. Crit Care Lond Engl. 2013;17:109.
14. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent J-L. Sepsis and septic shock. Nat Rev Dis Prim. 2016;2:16045.
15. Alejandria MM, Lansang MAD, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst. Rev. 2013;16(9):CD001090.
16. Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M. Bench-to-bedside review: immunoglobulin therapy for sepsis—biological plausibility from a critical care perspective. Crit Care Lond Engl. 2012;16:206.
17. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793–800.
18. Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care. 2005;20:239–49.
19. Welte T, Dellinger RP, Ebelt H, Ferrer M, Opal SM, Schliephake DE, et al. Concept for a study design in patients with severe community-acquired pneumonia: a randomised controlled trial with a novel IGM-enriched immunoglobulin preparation—The CIGMA study. Respir Med. 2015;109:758–67.
20. Giamarellos-Bourboulis EJ, Tziolos N, Routsi C, Katsenos C, Tsangaris I, Pneumatikos I, et al. Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins. Clin Microbiol Infect. 2016;22:499–506.
21. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35:2677–85.